Autolus Therapeutics’ (AUTL) “Buy” Rating Reiterated at Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They currently have a $9.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 141.29% from the stock’s previous […]

Leave a Reply

Your email address will not be published.

Previous post Reviewing Nano Labs (NASDAQ:NA) & Atomera (NASDAQ:ATOM)
Next post Tesla Stock Soars as Musk-Trump Alliance Sparks Investor Optimism